ӳ��ý

Publications

SARS-CoV-2 Nsp15 antagonizes the cGAS-STING-mediated antiviral innate immune responses.

Chiu HP, Yeo YY, Lai TY, et al. SARS-CoV-2 Nsp15 antagonizes the cGAS-STING-mediated antiviral innate immune responses. bioRxiv : the preprint server for biology. 2024. doi:10.1101/2024.09.05.611469

SARS-CoV-2 Nsp15 antagonizes the cGAS-STING-mediated antiviral innate immune responses.

Chiu HP, Yeo YY, Lai TY, et al. SARS-CoV-2 Nsp15 antagonizes the cGAS-STING-mediated antiviral innate immune responses. bioRxiv : the preprint server for biology. 2024. doi:10.1101/2024.09.05.611469

SARS-CoV-2 Nsp15 antagonizes the cGAS-STING-mediated antiviral innate immune responses.

Chiu HP, Yeo YY, Lai TY, et al. SARS-CoV-2 Nsp15 antagonizes the cGAS-STING-mediated antiviral innate immune responses. bioRxiv : the preprint server for biology. 2024. doi:10.1101/2024.09.05.611469

The global epidemic of early-onset cancer: Nature, nurture, or both?

Ogino S, Ugai T. The global epidemic of early-onset cancer: Nature, nurture, or both?. Annals of oncology : official journal of the European Society for Medical Oncology. 2024. doi:10.1016/j.annonc.2024.08.2336

The global epidemic of early-onset cancer: Nature, nurture, or both?

Ogino S, Ugai T. The global epidemic of early-onset cancer: Nature, nurture, or both?. Annals of oncology : official journal of the European Society for Medical Oncology. 2024. doi:10.1016/j.annonc.2024.08.2336

The global epidemic of early-onset cancer: Nature, nurture, or both?

Ogino S, Ugai T. The global epidemic of early-onset cancer: Nature, nurture, or both?. Annals of oncology : official journal of the European Society for Medical Oncology. 2024. doi:10.1016/j.annonc.2024.08.2336

The global epidemic of early-onset cancer: Nature, nurture, or both?

Ogino S, Ugai T. The global epidemic of early-onset cancer: Nature, nurture, or both?. Annals of oncology : official journal of the European Society for Medical Oncology. 2024. doi:10.1016/j.annonc.2024.08.2336

Frequent CHD1 deletions in prostate cancers of African American men is associated with rapid disease progression.

Diossy M, Tisza V, Li H, et al. Frequent CHD1 deletions in prostate cancers of African American men is associated with rapid disease progression. NPJ precision oncology. 2024;8(1):208. doi:10.1038/s41698-024-00705-8

Frequent CHD1 deletions in prostate cancers of African American men is associated with rapid disease progression.

Diossy M, Tisza V, Li H, et al. Frequent CHD1 deletions in prostate cancers of African American men is associated with rapid disease progression. NPJ precision oncology. 2024;8(1):208. doi:10.1038/s41698-024-00705-8

Frequent CHD1 deletions in prostate cancers of African American men is associated with rapid disease progression.

Diossy M, Tisza V, Li H, et al. Frequent CHD1 deletions in prostate cancers of African American men is associated with rapid disease progression. NPJ precision oncology. 2024;8(1):208. doi:10.1038/s41698-024-00705-8